• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kimball Electronics, Inc. Announces Appointment of Additional Director

    9/15/22 4:05:00 PM ET
    $BHC
    $KE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Electrical Products
    Technology
    Get the next $BHC alert in real time by email

    Kimball Electronics, Inc. (NASDAQ:KE), announces the expansion of its Board of Directors and appointment of a new director at its regularly scheduled Board Meeting on September 13, 2022.

    Tom Vadaketh was selected to the Company's Board of Directors (the "Board"), effective as of the September meeting. Mr. Vadaketh will serve on the Audit Committee and will stand for election to a full term at the 2022 Annual Meeting of Share Owners in November.

    Mr. Vadaketh serves as Chief Financial Officer of Bausch Health (NYSE:BHC) (TSX:BHC), which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices globally, primarily in the therapeutic areas of eye-health, gastroenterology, and dermatology.

    Prior to joining Bausch Health in January 2022, Mr. Vadaketh served as Executive Vice President and Chief Financial Officer of eResearch Technology, Inc. from September 2018 to December 2021, where he was responsible for leading the Finance function including controllership, treasury, taxation, and financial planning.

    Prior to that, he was Executive Vice President and Chief Financial Officer of Cambrex Corporation. In addition, Mr. Vadaketh spent over 20 years at Procter & Gamble and Tyco International, where he held several roles of increasing responsibility at both companies.

    Mr. Vadaketh received a degree from the Institute of Chartered Accountants in England and Wales (ACA) and an M.B.A. from Manchester Business School. He is a Certified Public Accountant.

    "Speaking on behalf of our Board, it is an honor to have Tom join us with his well-rounded financial expertise, vast experience with major multinational organizations, and demonstrated leadership in a variety of global businesses driving both organic growth and strategic acquisitions," said Don Charron, Chairman of the Board and Chief Executive Officer. "Tom further enhances our Board's distinct and valuable skill sets as we continue to build lasting relationships and global success with our stakeholders. We expect to learn a lot from Tom so that we become an even better company while creating quality for life."

    About Kimball Electronics, Inc.

    Kimball Electronics is a multifaceted manufacturing solutions provider of electronics and diversified contract manufacturing services to customers around the world. From our operations in the United States, China, India, Japan, Mexico, Poland, Romania, Thailand, and Vietnam, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values personal and organizational commitment to quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (NASDAQ:KE) is headquartered in Jasper, Indiana.

    To learn more about Kimball Electronics, visit: www.kimballelectronics.com.

    Lasting relationships. Global success.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005963/en/

    Get the next $BHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHC
    $KE

    CompanyDatePrice TargetRatingAnalyst
    Bausch Health Companies Inc.
    $BHC
    12/9/2025$8.00Equal Weight
    Barclays
    Kimball Electronics Inc.
    $KE
    8/15/2024Buy → Neutral
    Sidoti
    Bausch Health Companies Inc.
    $BHC
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    Bausch Health Companies Inc.
    $BHC
    7/10/2024$8.00Mkt Perform
    Raymond James
    Kimball Electronics Inc.
    $KE
    10/9/2023$39.00Buy
    B. Riley Securities
    Bausch Health Companies Inc.
    $BHC
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    Bausch Health Companies Inc.
    $BHC
    6/16/2023Outperform → Market Perform
    TD Cowen
    Kimball Electronics Inc.
    $KE
    6/15/2023$3.40Overweight
    Cantor Fitzgerald
    More analyst ratings

    $BHC
    $KE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Leung Sandra

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:30:13 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Paulson John

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:20:34 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wechsler Amy B

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:19:05 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Bausch Health with a new price target

    Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00

    12/9/25 8:43:03 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics downgraded by Sidoti

    Sidoti downgraded Kimball Electronics from Buy to Neutral

    8/15/24 7:57:54 AM ET
    $KE
    Electrical Products
    Technology

    Bausch Health downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

    8/2/24 7:25:50 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Paulson & Co. Inc. bought $15,625,000 worth of shares (2,500,000 units at $6.25) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    11/28/25 5:38:39 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $312,490,062 worth of shares (34,721,118 units at $9.00) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/14/25 9:35:28 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $21,267,731 worth of shares (3,243,049 units at $6.56) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/13/25 6:51:24 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kimball Electronics Inc.

    SCHEDULE 13G/A - Kimball Electronics, Inc. (0001606757) (Subject)

    3/27/26 10:18:42 AM ET
    $KE
    Electrical Products
    Technology

    Kimball Electronics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Kimball Electronics, Inc. (0001606757) (Filer)

    3/19/26 4:34:47 PM ET
    $KE
    Electrical Products
    Technology

    Bausch Health Companies Inc. filed SEC Form 8-K: Leadership Update

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    3/2/26 5:17:03 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

    Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the 2026 ASPIRE HIGHER Scholarship Program, with applications open through June 10, 2026. The program will award six exceptional students, impacted by dermatologic conditions with scholarships of up to $10,000 each to support their pursuit of higher education. "It is an honor to continue the AS

    3/26/26 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics Releases 2025 Annual Sustainability Report

    Kimball Electronics, Inc. (NASDAQ:KE) today announced the release of its 2025 Guiding Principles Report, which includes the company's annual sustainability disclosures. Themed "Building Tomorrow, Together," the Report outlines progress on environmental, social, and governance (ESG) initiatives and reflects the company's continued focus on the issues that matter most—where it can make a meaningful and lasting difference for people and the environment, while supporting long-term business success. About the Report Now in its seventh edition, the Report reflects how Kimball Electronics integrates sustainability into every area of its business, guided by its Guiding Principles: Customers, Pe

    3/19/26 9:15:00 AM ET
    $KE
    Electrical Products
    Technology

    $BHC
    $KE
    Leadership Updates

    Live Leadership Updates

    View All

    Kimball Electronics Intensifies Focus on Strategic Development With Appointment of a New Member to Its Leadership Team; Company to Participate at the Piper Sandler 37th Annual Healthcare Conference

      Kimball Electronics, Inc. (NASDAQ:KE) today announced the Company is intensifying its focus on strategic development with the appointment of a new member to its leadership team. Andrew D. Regrut, Treasurer and Investor Relations Officer, will now also lead the strategic development efforts of the Company. Commenting on Mr. Regrut's expanded role, Jana T. Croom, Chief Financial Officer, stated, "I'm thrilled to be announcing Andy's promotion and addition to our leadership team. He has been instrumental in our recent efforts to optimize debt levels through improved working capital management and global cash movement. We look for his energy and intensity to elevate our focus on strategic d

    12/2/25 8:30:00 AM ET
    $KE
    Electrical Products
    Technology

    Bausch Health Appoints New Chief Medical Officer and Head of R&D

    LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

    12/2/24 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Appoints Michele Holcomb, PhD, to Board of Directors

    Strategic healthcare leader brings more than 30 years of global experience to PureTech's Board following notable positions with Cardinal Health, Teva Pharmaceuticals and McKinsey & Company PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Michele Holcomb, PhD, will join its board of directors as an independent non-executive director. Dr. Holcomb's appointment will take effect as of September 23, 2024. She brings more than 30 years of expertise leading global healthcare companies through strategic inflection points and preparing in

    8/22/24 2:00:00 AM ET
    $KE
    $PRTC
    Electrical Products
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kimball Electronics Inc.

    SC 13G/A - Kimball Electronics, Inc. (0001606757) (Subject)

    11/12/24 3:47:56 PM ET
    $KE
    Electrical Products
    Technology

    Amendment: SEC Form SC 13G/A filed by Kimball Electronics Inc.

    SC 13G/A - Kimball Electronics, Inc. (0001606757) (Subject)

    11/4/24 11:46:47 AM ET
    $KE
    Electrical Products
    Technology

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $KE
    Financials

    Live finance-specific insights

    View All

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basisGAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7%BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTSDelivered eleventh consecutive quarter of year-over-y

    2/18/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kimball Electronics Reports Q2 Results; With Strong Sales Growth in the Medical Vertical; Company Raises Its Guidance for Fiscal 2026

    Second Quarter 2026 Highlights Revenue of $341.3 million, a 5% decrease compared to Q2 of fiscal 2025 Sales in the medical vertical increased 15% year-over-year Operating income of $10.8 million, or 3.2% of net sales Adjusted operating income of 4.5%, up 80 bps year-over-year Cash from operations of $6.9 million, the eighth consecutive quarter of positive operating cash generation Debt of $154.2 million and borrowing capacity of $285.1 million Cash Conversion Days of 91, a 16-day improvement compared to the same period last year Invested $4.3 million to repurchase 149,000 shares of common stock Company increases guidance for fiscal 2026 sales and adjusted operatin

    2/4/26 4:08:00 PM ET
    $KE
    Electrical Products
    Technology